Joshua Tobias

7PUBLICATIONS
28CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsComposite and hybrid materialsInnate immunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 27, 2024
SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity.

Joshua Tobias, Peter Steinberger, Joy Wilkinson

|Jul 19, 2024
Phase II Trial of HER-Vaxx, a B-cell Peptide-Based Vaccine, in HER2-Overexpressing Advanced Gastric Cancer Patients Under Platinum-Based Chemotherapy (HERIZON).

Joshua Tobias, Marina Maglakelidze, Zoran Andrić

|Jan 11, 2024
Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion.

Joshua Tobias, Sandra Högler, Martin Raigel

|Jan 21, 2023
A Biomimetic, Silaffin R5-Based Antigen Delivery Platform.

Daniela Reichinger, Manuel Reithofer, Mariam Hohagen

|Nov 26, 2022
Combined Vaccination with B Cell Peptides Targeting Her-2/neu and Immune Checkpoints as Emerging Treatment Option in Cancer.

Joshua Tobias, Mirjana Drinić, Anna Schmid

|May 21, 2022
NKG2A-checkpoint inhibition and its blockade critically depends on peptides presented by its ligand HLA-E.

Claire Battin, Gabriel Kaufmann, Judith Leitner

Pageof 2

Frequent Collaborators

4 joint publications

Ursula Wiedermann

4 joint publications

Michael Kundi

3 joint publications

Peter Steinberger

3 joint publications

Erika Garner-Spitzer